The role of the epidermal growth factor in the pathogenesis of schizophrenia. Clinical and diagnostic value
Daria Piskareva1, Yana Zorkina1, Alisa Andryushenko1
1Scientific Clinical Research Centre of Neuropsychiatry, Moscow, Russia.
Abstract:
Research increasingly implicates neuroimmune inflammation in schizophrenia, with the epidermal growth factor (EGF) family as a potential link. This review critically evaluates EGF family members as diagnostic, risk, and treatment response markers.The most consistent finding is decreased serum EGF in chronic schizophrenia, confirmed in postmortem brain and independent of antipsychotics. First-episode data are heterogeneous, reflecting differences in medication status, population, and illness stage.Genetic studies of EGF rs4444903 show no consistent disease risk association but demonstrate a replicable, sex-specific effect on age at onset in males. Stronger evidence implicates NRG1 type IV and NRG3 polymorphisms in disease biology.Serum EGF is not a reliable treatment response marker. In summary, EGF alone is not clinically useful. Its value lies in consistent reduction in chronic patients, sex-specific effects on age at onset, and robust links of NRG1 and NRG3 to schizophrenia.
Related Concept Videos
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Clinical Applications of Epidermal Stem Cells
Psychological and Sociocultural Causes of Schizophrenia
Mitogens and the Cell Cycle
Schizophrenia


